title: [To investigate the opportunity of entecavir treatment for HBeAg-negative acute-on-chronic liver].
abstract: OBJECTIVE
  To explore relations between the opportunities and effects of internal general treatment added Entecavir on acute-on-chronic liver failure (ACLF) of HBeAg-negative chronic hepatitis B in different score ranges of acute-on-chronic liver failure severity.
  
  
  METHODS
  A total of 108 ACLF of HBeAg-negative chronic hepatitis B patients with different ACLF severity score were treated with internal general treatment added Entecavir. The liver failure severity scores, HBV-DNA loads during the initiation of therapy, recovery phase and in deathbed phase, courses of Entecavir administration and mortalities were studied.
  
  
  RESULTS
  For 19 patients with high ACLF score (> or = 12), the difference in ACLF score between pre and post-treatment was not significant. The difference in HBV-DNA load between pre and post-treatment was not significant and the mortality was 18/19. For 30 patients with higher intermediate ACLF score (8-11), the difference in ACLF score between pre and post-treatment was not significant. The difference in HBV-DNA load between pre and post-treatment was significant, and the mortality was 66.67% (20/30). For 36 patients with lower intermediate ACLF score (5-7), the difference in ACLF score between pre and posttreatment was not significant. The difference in HBV-DNA load between pre and post-treatment was significant, and the mortality was 30.56% (11/36). For 23 patients with low ACLF score (< or = 4), the difference in ACLF score between pre and post-treatment was significant. The difference in HBV-DNA load between pre and post-treatment was significant, and the mortality was 8.70% (2/23).
  
  
  CONCLUSIONS
  A novel acute-on-chronic liver failure scoring system can syllabify differentiate the relations between the opportunities and efficacies on the Entecavir treatment for HBeAg-negative ACLF.
authors.affiliation: Department of Infectious Deseases, The Third Affiliated Hospital of SUN Yat-sen University, Guangzhou 510630, China.
authors.forename: Li
authors.initials: L
authors.lastname: Mai
authors.affiliation: Department of Infectious Deseases, The Third Affiliated Hospital of SUN Yat-sen University, Guangzhou 510630, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Yan
authors.affiliation: Department of Infectious Deseases, The Third Affiliated Hospital of SUN Yat-sen University, Guangzhou 510630, China.
authors.forename: Shao-Quan
authors.initials: SQ
authors.lastname: Zhang
authors.affiliation: Department of Infectious Deseases, The Third Affiliated Hospital of SUN Yat-sen University, Guangzhou 510630, China.
authors.forename: Wei-Min
authors.initials: WM
authors.lastname: Ke
authors.affiliation: Department of Infectious Deseases, The Third Affiliated Hospital of SUN Yat-sen University, Guangzhou 510630, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Cao
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006513:Hepatitis B e Antigens / Q000097:blood*; D006515:Hepatitis B virus / Q000235:genetics / Q000302:isolation & purification* / Q000378:metabolism; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D017093:Liver Failure / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; C413685:entecavir; D006147:Guanine